Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

Robinson, Stephen P

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. [electronic resource] - Blood Dec 2002 - 4310-6 p. digital

Publication Type: Comparative Study; Journal Article; Multicenter Study

0006-4971

10.1182/blood-2001-11-0107 doi


Adult
Aged
Alemtuzumab
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--administration & dosage
Antilymphocyte Serum
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bone Marrow Transplantation
Carmustine--administration & dosage
Cohort Studies
Cytarabine--administration & dosage
Disease Progression
Drug Resistance, Neoplasm
Europe--epidemiology
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease--epidemiology
Hodgkin Disease--drug therapy
Humans
Immunosuppressive Agents--therapeutic use
Life Tables
Lymphoma, Non-Hodgkin--drug therapy
Male
Melphalan--administration & dosage
Middle Aged
Peripheral Blood Stem Cell Transplantation--adverse effects
Podophyllotoxin--administration & dosage
Proportional Hazards Models
Salvage Therapy
Survival Analysis
Survival Rate
Transplantation Chimera
Transplantation Conditioning
Transplantation, Homologous--adverse effects
Treatment Outcome
Vidarabine--administration & dosage